Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MDM4 | O15151 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | TLR2 | O60603 | 2/20 | 0.57 |
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354378 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL30338216 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL29908078 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL29400089 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL1025352 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL14997839 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL12658035 | 0.95 | PTPN1 (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL14719947 | 0.93 | KMT2A (0.57) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL22712859 | 0.93 | TLR2 (0.54) | KMT2AMDM4TP53TLR2CASP3 | |
| D-Glutamate SCHEMBL28574794 | 0.93 | MDM4 (0.52) | KMT2AMDM4TP53TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118005719-A | SIRP alpha blocker polypeptide, construction method and application thereof | 华东理工大学 | 2024-05-10 | — | — | CN | claimed |
| CN-115340472-B | Glutamic acid derivative and synthesis method and application thereof | 合肥工业大学 | 2024-05-07 | — | — | CN | claimed |
| CN-117224690-B | Gamma-polyglutamic acid mixture, composition and preparation method as auxiliary agent | 江苏海王健康生物科技有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-115844790-A | Hair conditioner and preparation method thereof | 北京普世安生物科技有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-120053682-A | Multi-drug linked combination drug conjugate and application thereof | 上海睿智医药研究集团有限公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-4469468-A1 | PROCESS FOR THE PREPARATION OF LINACLOTIDE | Fresenius Kabi iPSUM S.r.l. (IT) | 2024-12-04 | — | — | EP | disclosed |
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| CN-118063551-A | Polypeptide with pH response antibacterial and enzyme response antioxidant functions and application thereof | 郑州大学 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024097320-A1 | AZOTOMYCIN PRODRUGS WITH PREFERENTIAL TUMOR DELIVERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-05-10 | — | — | WO | disclosed |
| CN-118005719-A | SIRP alpha blocker polypeptide, construction method and application thereof | 华东理工大学 | 2024-05-10 | — | — | CN | disclosed |
| CN-115340472-B | Glutamic acid derivative and synthesis method and application thereof | 合肥工业大学 | 2024-05-07 | — | — | CN | disclosed |
| CN-102149411-A | Method for acylating a peptide or protein | NOVO NORDISK AS | 2011-08-10 | — | — | CN | disclosed |
| EP-1961764-B1 | SUGAR CHAIN ADDUCT OF PEPTIDE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT | SHIONOGI & CO (JP) | 2011-05-11 | — | — | EP | disclosed |
| US-20100016547-A1 | Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016547-A1 | Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2010-01-21 | — | — | US | disclosed |
| CN-101434645-A | Synthetic oligopeptide and uses thereof | UNIV CHINA AGRICULTURAL (CN) | 2009-05-20 | — | — | CN | disclosed |
| US-20080207625-A1 | Synthesis and Purification of Pteroic Acid and Conjugates Thereof | ENDOCYTE, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1961764-A1 | SUGAR CHAIN ADDUCT OF PEPTIDE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT | Shionogi Co., Ltd. (JP) | 2008-08-27 | — | — | EP | disclosed |
| US-7220414-B2 | Degradable polyacetal polymers | A.P. PHARMA, INC. (US) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016547-A1 | Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient | GLP1R, VIP, IAPP | KMT2A 2957/4885MDM4 4750/4885TP53 4366/4885 |
| US-20080207625-A1 | Synthesis and Purification of Pteroic Acid and Conjugates Thereof | DHFR, SLC46A1, FOLR1 | KMT2A 1493/4885MDM4 2643/4885TP53 1577/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | KMT2A 496/4885MDM4 2717/4885TP53 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.